Powerful.
Persistent.
Switchable.
Next generation immunotherapies
for hard-to-treat cancers.
Allogeneic + Switchable
Addressing the shortcomings of current T cell-based immunotherapies
with powerful, targeted, safe technology.
Powerful
Proprietary platforms allow for powerful controllability of CAR-T reactivity while maintaining high anti-tumor activity that prevents T-effector cell exhaustion and immune-suppression.
Targeted
Switchable on/off mechanism made possible by combining a universal effector cell with soluble adaptors called Targeting Modules (TMs) allows for precise targeting of cancer antigens.
Safe
Rapid switchability lowers the risk for acute and long-term CRS-related and other side effects, opening a potentially improved therapeutic window for clinical application and increased safety.
Patient-focused.
Science-based.
Our mission is to overcome the limitations of current CAR-T cell therapies by introducing the next generation of immunotherapies to patients, everywhere.
A Promising Future
Our proprietary platforms — Universal Switchable CAR and TCE — promise significant advantages over current immunotherapies with improved therapeutic windows and outcomes.
Industry-Leading Experts
Behind all that we do at AvenCell is our distinguished board of the industry’s top experts. They bring years of experience to the company and help shape, guide, and position AvenCell for continued success.
